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ABSTRACT
Background: Atrial fibrillation is the most common arrhythmia in post-industrialized 
populations. Older age, hypertension, obesity, chronic inflammation, and diabetes are 
significant atrial fibrillation risk factors, suggesting that modern urban environments may 
promote atrial fibrillation. 
Objective: Here we assess atrial fibrillation prevalence and incidence among tropical 
horticulturalists of the Bolivian Amazon with high levels of physical activity, a lean diet, 
and minimal coronary atherosclerosis, but also high infectious disease burden and 
associated inflammation. 
Methods: Between 2005–2019, 1314 Tsimane aged 40–94 years (52% female) and 
534 Moseten Amerindians aged 40–89 years (50% female) underwent resting 12-lead 
electrocardiograms to assess atrial fibrillation prevalence. For atrial fibrillation incidence 
assessment, 1059 (81% of original sample) Tsimane and 310 Moseten (58%) underwent 
additional ECGs (mean time to follow up 7.0, 1.8 years, respectively). 
Findings: Only one (male) of 1314 Tsimane (0.076%) and one (male) of 534 Moseten 
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case in 7395 risk years for the 1059 participants with >1 ECG (incidence rate = 0.14 per 
1,000 risk years). No new cases were detected among Moseten, based on 542 risk years. 
Conclusion: Tsimane and Moseten show the lowest levels of atrial fibrillation ever 
reported, 1/20 to ~1/6 of rates in high-income countries. These findings provide additional 
evidence that a subsistence lifestyle with high levels of physical activity, and a diet low in 
processed carbohydrates and fat is cardioprotective, despite frequent infection-induced 
inflammation. Findings suggest that atrial fibrillation is a modifiable lifestyle disease 
rather than an inevitable feature of cardiovascular aging. 
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia in the post-industrialized world [1, 2]. It 
is associated with a five-fold increase in the risk of stroke [3], which is the second leading cause 
of death in many industrialized nations [4]. AF is also associated with a three-fold increase in 
risk of heart failure and two-fold increases in risk of dementia and all-cause mortality [3, 4]. The 
incremental cost of atrial fibrillation to the health care system has been estimated at 6–26 billion 
dollars per year in the United States alone [5].
AF prevalence is increasing worldwide due to its greater incidence among older adults and the 
aging of the global population [6, 7]. AF prevalence in the U.S. is expected to increase up to 45% 
by 2030, to over 12 million cases [8], and to 14–17 million cases across Europe [9]. The increasing 
prevalence of potentially modifiable AF risk factors contributes to its growing prevalence [6]. AF 
risk factors include older age, hypertension, congestive heart failure, diabetes, peripheral vascular 
and coronary artery disease, valvular heart disease, alcohol excess, sleep apnea, systemic 
inflammation, male sex, and other cardiovascular disease risk factors (e.g. low high-density 
lipoprotein, HDL) [3, 4, 6, 10]. Correlates of AF observed on a 12-lead electrocardiogram (ECG) 
include first-degree atrioventricular blocks, increased QRS duration, and bundle branch blocks [11]. 
Given the widespread and increasing prevalence of AF in post-industrialized populations, and its 
detection worldwide [12], AF has been considered a natural consequence of cardiovascular aging 
[13]. However, most estimates to date have been derived from high-income countries with more 
sedentary lifestyles. Prevalence and incidence rates appear to be generally lower in low-income 
countries, although country-level differences are not well explained by development status 
[12]. Thus, the relative roles of lifestyle and the biology of aging in AF incidence across diverse 
environments remain unclear.
STUDY GOALS AND HYPOTHESES
To assess the extent to which lifestyle factors influence AF risk, we evaluate AF prevalence and 
incidence in the Tsimane and Moseten, two subsistence-based populations of lowland Bolivia with 
active lifestyles [14]. The Tsimane are an indigenous population of approximately 17,000 who 
fish, hunt, farm with hand tools, and forage for their food; they have minimal access to electricity, 
clean water, and public sanitation [15]. The Moseten (population ~3,000) are a genetically and 
ethno-linguistically related Bolivian population of horticulturalists who live in close proximity 
to Tsimane but who began acculturation into broader Bolivian society decades earlier [16]. The 
Tsimane mostly inhabit the Maniqui River basin area in the municipality of San Borja, while the 
Moseten territory is adjacent but closer to the Andes foothills west of the Tsimane area in the 
municipality of Palos Blancos. There is limited inter-marriage between Tsimane and Moseten, as 
their territories do not overlap. While Tsimane are largely endogamous, the Moseten in recent 
decades have intermarried with highland migrants to the region. Working with the Tsimane 
and Moseten to assess AF provides a rare opportunity to evaluate the extent to which lifestyle 
and environment might effectively reduce AF, beyond that of healthy subjects in industrialized 
nations. Tsimane have the lowest levels of coronary atherosclerosis ever observed, based on 
non-contrast X-ray computed tomography (CT) to evaluate coronary artery calcification [17]. 
Tsimane exhibit few other atherosclerotic risk factors, including hypertension [18], obesity, type 
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2 diabetes, and hyperlipidemia [17, 19]. Tsimane diet is rich in fiber, polyunsaturated fatty acids, 
potassium, magnesium, and selenium [16], and low in saturated fat and preservatives. They have 
high physical activity levels beginning early in life [14].Though endurance-trained athletes show 
evidence of increased frequency of paroxysmal AF [20], the Tsimane do not typically engage in very 
high levels of vigorous activity. Instead, the Tsimane engage in high levels of low and moderate 
activity, and thus are rarely sedentary, throughout the day [14]. They show no evidence of lower 
extremity peripheral atherosclerosis as assessed by Ankle-Brachial Indices [21]. However, two AF 
risk factors that are prevalent among Tsimane include elevated levels of systemic inflammation, 
and low levels of high-density lipoproteins (HDL) [17, 21]. Inflammation has been associated 
with increased AF prevalence in numerous studies [22–24], and the Tsimane experience frequent 
infections, which increases systemic inflammation and immune activation throughout life [25, 
26]. Low HDL is also a significant AF risk factor [27], and over half of Tsimane adults age 40+ years 
show HDL levels < 40 mg/dL [17]. 
Compared to Tsimane, Moseten lifestyle is more acculturated: Moseten have more schooling, have 
greater access to clean water and electricity, and many no longer speak the indigenous Moseten 
language but instead are monolingual Spanish speakers. Moseten also engage more often in cash 
cropping than Tsimane and have greater access to labor-saving technology, like chainsaws. Likely 
as a result of these differences, the Moseten show higher rates of obesity and type 2 diabetes, 
and have more processed foods and additives in their diet [16]. Nevertheless, compared to 
populations in high-income countries, Moseten lifestyle as subsistence farmers is still closer to that 
of the horticultural-forager Tsimane in terms of physical activity level and other AF risk factors. 
Investigating Moseten AF thus represents an opportunity to explore the role of lifestyle change on 
AF in a genetically related population inhabiting a similar rural environment within Bolivia. 
Our aims are to (1) assess risk factors for AF among Tsimane and Moseten; and (2) estimate their 
AF prevalence and incidence and compare against other world populations.
METHODS
RISK FACTORS
Baseline demographic information was collected by a mobile biomedical team along with 
measurements of the following risk factors: height, weight, waist circumference, blood lipids (total 
cholesterol, LDL, HDL and triglycerides) from fasting morning samples, inflammatory markers 
(high sensitivity C-reactive protein [hs-CRP], erythrocyte sedimentation rate [ESR], interleukin-6 
[IL6]), and systolic and diastolic blood pressure (see 17, 18 for detailed procedures) [17, 18]. 
Hypertension and diabetes were classified according to clinical guidelines [28].
AF PREVALENCE AND INCIDENCE
Trained Bolivian physicians (RQG, ECL, DER) conducted a resting standard 12-lead electrocardiogram 
(ECG). Tsimane ECGs were reviewed by two cardiologists (CJR and KT) blinded to subject information 
and independently evaluated by three cardiologists (GST, MIM, LSW). Moseten ECGs were reviewed 
by one of the same cardiologists (CJR) and an additional cardiologist (MAE). ECGs were coded as 
either positive or negative for AF. There was no disagreement in diagnoses among coders. ECG 
measures of PR and QRS were also recorded. 
To assess AF prevalence, at least one ECG was performed from 2005–2019 on 1314 Tsimane aged 
40+ years, which at the time represented 70% of the adult population in that age range (Table 1; 
Figure S1 for STROBE sample flow chart). AF was defined as in the 2006 ACC/AHA/ESC guidelines 
[29]. Participants also underwent routine medical screening by a mobile medical team consisting 
of internists, medical technicians, and biochemists. A patient’s first ECG was used to assess AF 
prevalence, and 81% (n = 1059) of the sample underwent at least one subsequent ECG to assess 
incidence. Between 2015 to 2018, one ECG was performed on 534 Moseten aged 40+ years by 
the same team and using the same protocol, covering 95% of the eligible population aged 40+. 
A second ECG was collected among 310 (58%) of these Moseten participants (Table 2, Figure S2). 
AGE GROUP (YEARS) N 39–49 50–59 60–69 70–79 ≥ 80 TOTAL SIGNIFICANCE
N with baseline ECG 670 328 204 90 22 1314
Proportion Male 0.52 0.51 0.55 0.49 0.36 0.52
Anthropometric measures
Height cm 1307 157.0 (7.2) 155.8 (7.7) 155.1 (7.4) 151.6 (7.9) 149.9 (6.2) 155.9 (7.5) <0.001
Weight kg 1307 60.4 (9.6) 58.4 (10.3) 56.3 (9.4) 53.2 (8.7) 47.8 (7.9) 58.5 (10.0) <0.001
BMI kg/m2 1306 24.4 (3.1) 24.0 (3.6) 23.3 (3.1) 23.1 (3.4) 21.2 (2.2) 24.0 (3.3) <0.001
% BMI > 30 kg/m2 1306 5.0 (0.8) 5.2 (1.2) 3.5 (1.3) 4.4 (2.2) 0.0 (0.0) 4.7 (0.6) 0.362
Waist Circ. in 1049 34.9 (3.3) 35.0 (4.1) 35.2 (3.7) 35.6 (4.0) 33.5 (2.4) 35.0 (3.6) 0.732
% Waist Circ. High 1049 24.6 (1.9) 26.0 (2.7) 31.1 (3.7) 25.0 (5.3) 5.9 (5.9) 25.6 (1.4) 0.938
Lipid profiles
Total Cholesterol mg/dL 1112 142.9 (27.6) 146.8 (30.6) 140.9 (26.9) 137.8 (27.6) 139.6 (26.5) 143.3 (28.4) 0.064
% Cholesterol > 240 mg/dL 1112 0.35 (0.25) 0.68 (0.48) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.36 (0.18) 0.498
LDL mg/dL 1032 86.6 (25.7) 89.7 (27.9) 85.0 (25.6) 80.3 (25.3) 82.5 (21.7) 86.7 (26.2) 0.045
% LDL > 130 mg/dL 1032 5.28 (0.97) 6.77 (1.54) 4.52 (1.67) 5.97 (2.92) 0.00 (0.00) 5.52 (0.71) 0.714
HDL mg/dL 1035 37.2 (7.5) 38.0 (6.7) 37.1 (6.4) 38.0 (7.6) 37.1 (9.6) 37.5 (7.2) 0.045
Triglycerides mg/dL 1117 109.0 (46.9) 113.9 (52.7) 106.1 (45.9) 105.9 (41.0) 105.6 (22.6) 109.6 (47.8) 0.519
% Triglycerides > 200 mg/dL 1117 4.20 (0.84) 4.76 (1.24) 4.29 (1.59) 1.37 (1.37) 0.00 (0.00) 4.12 (0.59) 0.289
Inflammatory Markers
hs-CRP mg/dL 758 2.4 (1.8) 2.6 (2.3) 3.1 (2.3) 2.3 (1.6) 4.4 (2.7) 2.6 (2.0) <0.001
% hs-CRP > 3 mg/dL 758 37.0 (2.5) 42.9 (3.4) 53.8 (4.6) 45.5 (7.6) 66.7 (14.2) 42.2 (1.8) <0.001
ESR mm/h 1304 27.1 (15.1) 30.3 (15.1) 38.8 (20.9) 43.7 (22.3) 58.4 (19.0) 31.4 (17.9) <0.001
% Elevated ESR 1304 45.6 (1.9) 59.3 (2.7) 72.3 (3.2) 76.4 (4.5) 95.5 (4.6) 56.1 (1.4) <0.001
IL6 (pm/mL) 740 1.6 (0.7) 1.6 (0.5) 1.6 (0.9) 1.6 (1.6) 1.5 (1.3) 1.6 (0.8) <0.001
Blood Pressure and Hypertension
Heart Rate (BPM) 1314 51.1 (26.0) 48.1 (27.6) 49.2 (28.4) 55.9 (29.5) 57.6 (26.4) 50.5 (27.1) 0.640
Systolic Blood Pressure mmHg 1305 111.1 (8.0) 114.4 (10.2) 118.0 (12.7) 121.9 (16.4) 121.5 (24.0) 113.9 (11.1) <0.001
% SBP > 120 mmHg 1305 11.3 (1.2) 19.9 (2.2) 34.2 (3.4) 45.6 (5.3) 38.1 (10.9) 19.8 (1.1) <0.001
Diastolic Blood Pressure mmHg 1305 69.7 (5.8) 70.8 (6.1) 71.6 (7.9) 70.8 (7.8) 68.2 (9.8) 70.3 (6.5) 0.004
% DBP > 80 mmHg 1305 3.3 (0.7) 6.8 (1.4) 11.4 (2.2) 7.8 (2.8) 4.8 (4.8) 5.8 (0.6) 0.002
% Hypertensive (>130/80 mmHg) 1305 3.8 (0.7) 8.9 (1.6) 20.3 (2.8) 26.7 (4.7) 9.5 (6.6) 9.3 (0.8) <0.001
ECG Measures
PR ms 1312 162 (19) 162 (19) 162 (18) 162 (20) 160 (21) 162 (19) 0.990
% PR > 200 ms 1312 1.79 (0.5) 2.44 (0.9) 2.46 (1.1) 3.37 (1.9) 4.56 (4.6) 2.21 (0.4) 0.328
QRS ms 1313 103 (12) 103 (12) 104 (17) 104 (18) 99 (14) 103 (14) 0.999
% QRS > 120 ms 1313 7.6 (1.0) 5.8 (1.3) 10.3 (2.1) 10.0 (3.2) 4.6 (4.6) 7.7 (0.7) 0.316
Coronary Calcium scores from CT scan
% CAC > 100 AU 823 0.5 (0.38) 3.5 (1.2) 8.5 (2.34) 4.4 (3.1) 30.8 (13.3) 3.5 (0.6) <0.001
Table 1 Tsimane sample composition and distribution of AF risk factors. Standard deviations and standard errors are given in parentheses (for 
means and proportions, respectively). Significance column provides p-values for testing differences across age groups based on ANOVA.
Note: Sample sizes vary, especially for serum biomarker analyses, due to logistical complications in the field (e.g., inability to store serum). CT 
sample sizes are smaller because of stratified sampling for ages 40–54.
AGE GROUP (YEARS) N 40–49 50–59 60–69 70–79 ≥ 80 TOTAL (AGE-
ADJUSTED)
SIGNIFICANCE
N with baseline ECG 208 155 121 39 10 534
Proportion Male 0.47 0.5 0.54 0.62 0.4 0.5
Anthropometric Measures
Height cm 527 156.1 (7.1) 154.8 (6.7) 153.3 (8.0) 151.8 (9.5) 150.6 (7.1) 154.8 (7.4) <0.001
Weight kg 523 64.5 (12.4) 62.6 (11.1) 58.2 (13.0) 58.2 (15.0) 60.5 (9.0) 62.4 (12.4) <0.001
BMI kg/m2 523 26.5 (5.1) 26.1 (4.2) 24.6 (4.7) 25.1 (5.3) 26.6 (3.3) 26.0 (4.8) 0.002
% BMI > 30 kg/m2 523 21.2 (2.9) 18.2 (3.1) 10.2 (2.8) 21.1 (6.7) 10.0 (10.0) 18.3 (1.7) 0.088
Lipid Profile
Total Cholesterol mg/dL 368 157.9 (30.1) 162.4 (37.8) 157.2 (35.2) 161.9 (24.9) 158.3 (34.5) 159.2 (33.0) 0.873
% Cholesterol > 240 mg/dL 368 2.9 (1.4) 4.5 (2.0) 2.3 (1.6) 0.0 (0.0) 0.0 (0.0) 3.0 (0.9) 0.28
LDL mg/dL 363 106.3 (35.7) 108.8 (37.9) 99.9 (35.8) 107.3 (27.4) 106.3 (30.3) 105.9 (35.7) 0.286
% LDL > 130 mg/dL 363 19.9 (3.4) 24.6 (4.1) 19.3 (4.2) 26.1 (9.4) 33.3 (21.1) 21.7 (2.2) 0.991
HDL mg/dL 363 37.6 (9.1) 36.5 (9.1) 39.2 (9.3) 37.8 (9.1) 35.1 (3.4) 37.6 (9.1) 0.193
Triglycerides mg/dL 365 137.9 (74.6) 134.2 (81.1) 113.0 (59.8) 135.0 (71.0) 103.1 (25.5) 131.8 (73.2) 0.047
% Triglycerides > 200 mg/dL 365 15.4 (3.1) 15.3 (3.4) 10.2 (3.3) 16.7 (7.8) 0.00 (0.00) 14.3 (1.9) 0.431
Inflammatory Markers
hs-CRP mg/dL 109 2.6 (2.7) 2.5 (2.1) 2.9 (3.0) 3.5 (1.9) 7.3 (0.0) 2.6 (2.7) 0.315
% hs-CRP > 3 mg/dL 109 47.4 (8.2) 42.1 (8.1) 50.0 (9.3) 50.0 (50.0) 100.0 (NA) 47.6 (5.9) 0.275
ESR mm/h 449 29.6 (17.3) 33.8 (20.4) 38.5 (22.0) 46.9 (24.1) 39.0 (21.3) 33.6 (19.6) <0.001
% Elevated ESR 449 49.7 (3.9) 60.2 (4.3) 64.4 (4.7) 84.9 (6.3) 70.0 (15.3) 57.8 (2.4) <0.001
IL6 (pm/mL) 114 1.6 (0.3) 1.6 (1.1) 1.6 (0.9) 7.8 (8.8) 13.3 (0.0) 1.6 (1.1) 0.259
Blood Pressure and Hypertension
Heart Rate (BPM) 533 64.0 (9.0) 65.3 (9.9) 64.4 (9.2) 69.5 (16.1) 67.8 (10.1) 64.9 (10.0) 0.019
Systolic Blood Pressure mmHg 526 116.9 (12.6) 118.9 (15.9) 125.0 (15.1) 130.8 (16.5) 144.8 (25.3) 120.3 (14.5) <0.001
SBP > 120 mmHg 526 35.8 (3.4) 39.2 (4.0) 55.4 (4.5) 71.1 (7.5) 90.0 (10.0) 43.5 (2.1) <0.001
Diastolic Blood Pressure mmHg 527 74.9 (10.1) 76.8 (11.6) 78.9 (10.2) 81.5 (9.3) 92.2 (15.2) 76.9 (10.6) <0.001
% DBP > 80 mmHg 527 26.5 (3.1) 33.1 (3.8) 39.7 (4.5) 47.4 (8.2) 80.0 (13.3) 32.9 (2.0) <0.001
% Hypertensive (>130/80 mmHg) 527 29.4 (3.2) 37.0 (3.9) 45.5 (4.6) 55.3 (8.2) 100.0 (0.0) 37.3 (2.1) <0.001
ECG Measures
PR ms 528 150 (19) 152 (20) 153 (20) 145 (21) 158 (33) 151 (20) 0.937
% PR > 200 ms 528 1.5 (0.8) 2.0 (1.1) 1.7 (1.2) 0.0 (0.0) 11.1 (11.1) 1.7 (0.6) 0.565
QRS ms 533 104 (13) 102 (10) 106 (17) 104 (15) 96 (8) 104 (13) 0.872
% QRS > 120 ms 533 4.3 (1.4) 4.5 (1.7) 10.7 (2.8) 15.4 (5.9) 0.0 (0.0) 6.2 (1.0) 0.018
Table 2 Moseten sample 
composition and distribution 
of AF risk factors. Standard 
deviations are given in 
parentheses (for means), 
standard error (for proportions). 
“Total” column provides sample 
means age-standardized to 
Tsimane sample age distribution. 
Significance column provides 
p-values for testing differences 
across age groups based on 
ANOVA.
To assess Tsimane incidence, all follow-up ECGs (n = 1059 individuals totaling 7395 risk years) 
were examined with an average time to follow-up of 7.0 years (Table 3). Moseten incidence is 
based on a smaller follow-up sample (n = 310 totaling 542 risk years; average time to follow-up 
= 1.8 years). Tsimane and Moseten adults age 40+ years not sampled in the prevalence phase or 
missed during the incidence phase show minimal differences in AF risk factors (Supplementary 
Table S1). 
VERBAL AUTOPSIES
We recognize that our estimates of AF prevalence and incidence may be biased due to potentially 
higher case fatality rates, given the limited medical treatment in the region. To investigate this 
possibility, one THLHP physician (RQG) and Tsimane assistant conducted verbal autopsies for all 
Tsimane deaths occurring between October 2008 and December 2013 (n = 209 deaths) using the 
2012 World Health Organization Verbal Autopsy Instrument [30].
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STATISTICAL ANALYSIS
Crude prevalences were determined by dividing the number of cases diagnosed with AF by the 
total number of participants undergoing their initial ECG. Crude incidence rates were calculated by 
dividing the total number of new cases diagnosed from the follow-up ECG by the number of risk 
years between baseline and last ECG (if all were negative) or between the negative and positive 
ECGs (if a new incidence occurred). 
To compare AF prevalence across populations, we selected papers reporting AF prevalence in 
rural subsistence-level samples (Ghana and Tanzania) [31, 32] and among indigenous groups 
living in industrialized nations (Indigenous Australians and Native Americans) [33–36]. We also 
selected studies in industrialized populations that were population representative, used similar 
methodology for AF diagnosis, and provided age-specific AF rates so that age-standardized 
rates could be calculated [37–40]. Lastly, we included recently published AF prevalences for 
Global Burden of Disease (GBD) world regions based on 184 studies, that used similar inclusion 
and exclusion criteria, and so may also include atrial flutter and paroxysmal AF [12]. We employ 
indirect standardization using age-specific AF prevalences from the GBD sample to compute 
comparable estimates of AF prevalence across populations (Figure 1). This was done to account 
for the different age ranges among samples, which prevented us from directly standardizing the 
age-specific prevalences of each sample to a standard population structure.
ETHICS STATEMENT
All phases of the study were approved by the Institutional Review Boards of the University of New 
Mexico Health Sciences Center and the University of California, Santa Barbara. Additionally, the 
Tsimane government (Gran Consejo Tsimane), village leaders, and study participants approved all 
protocols. 
AGE GROUP (YEARS) 40–49 50–59 60–69 70–79 ≥ 80 TOTAL
TSIMANE
Number of individuals 670 328 204 90 22 1314
Number of AF cases 0 0 0 1 0 1
AF prevalence (per 1,000) 0 0 0 11.11 0 0.76
N with >1 ECG 541 286 157 60 15 1059
Total Person-Years 3726 2190 1074 335 70 7395
Average Risk Years per Person 6.89 7.66 6.84 5.59 4.67 6.98
Number of new AF cases 0 0 0 0 1 1
AF incidence (per 1,000 person years) 0 0 0 0 14.29 0.14
MOSETEN
Number of individuals 208 156 121 39 10 534
Number of AF cases 0 0 0 1 0 1
AF prevalence (per 1,000) 0 0 0 25.64 0 1.87
N with > 1 ECG 96 92 88 25 9 310
Total Person-Years 170 162 153 43 14 542
Average Risk Years per Person 1.78 1.76 1.74 1.73 1.55 1.75
Number of new AF cases 0 0 0 0 0 0
AF incidence (per 1,000 person years) 0 0 0 0 0 0
Table 3 Crude prevalence and 
incidence of atrial fibrillation.
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Tsimane and Moseten adults are short in stature (mean = 156 and 155 cm, respectively) with a 
corresponding low body weight (mean ~59 and 62 kg, respectively) (Tables 1, 2). Mean body mass 
index (BMI) for Tsimane is 24 kg/m2 and 5% of adults are obese (BMI ≥ 30 kg/m2). Moseten show 
larger mean BMI (26.0 kg/m2) and higher obesity prevalence (18%). 
Tsimane total fasting cholesterol levels are low (mean = 143 mg/dL, and < 1% have an elevated 
value ≥ 240 mg/dL. Low-density lipoproteins (LDLs) and triglycerides are also low (mean = 87 and 
110 mg/dL, respectively). Only 5.5% had LDL ≥ 130 mg/dL and 4% had triglycerides ≥ 200 mg/dL. 
HDL values were also low (mean = 37.5 mg/dL). Moseten show higher levels of most blood lipids: 
mean total cholesterol is 159 mg/dL (3% with levels ≥ 240 mg/dL), mean LDL is 106 (22% ≥ 130 
mg/dL), mean triglycerides are 132 mg/dL (14% ≥ 200 mg/dL). Only Moseten HDLs (mean = 37.6 
mg/dL) are similar to Tsimane levels. 
Inflammatory markers are elevated among both Tsimane and Moseten. Median levels of hs-
CRP are 2.6 mg/dL for both populations, and nearly half of adults show values > 3.0 mg/dL. ESR 
is also high and increases with age in both populations: 56% of Tsimane and 58% of Moseten 
show elevated ESR levels. Interleukin-6 (IL-6) levels are also high, especially at older ages among 
Moseten (Table 2). Blood pressure (BP) among the Tsimane participants is low, with mean systolic 
and diastolic BP being 114 mmHg and 70 mmHg, respectively (see also Gurven, Blackwell, Eid, 
Stieglitz, and Kaplan) [18]. Tsimane hypertension (> 130 mmHg systolic and/or 80 mmHg diastolic) 
is minimal (9% prevalence) compared to Moseten (37% prevalence).
Prevalence of first-degree block (PR > 200 ms) was rare in both Tsimane and Moseten populations 
(2%). Across both populations, 6–8% had QRS > 120 ms. Resting heart rates are relatively low, 
averaging 50.5 and 64.9 beats per minute among Tsimane and Moseten, respectively.
Coronary artery disease as assessed by non-contrast CT scan of coronary calcium (CAC) is largely 
absent among Tsimane. Mean CAC values range from < 2 Agaston units (AU) for adults aged 40–49 
to 68 AU for adults aged 80+ years. Overall, only 3.5% of Tsimane aged 40+ years have a CAC score 
over 100 AU (considered moderate risk) [17]. Analysis of CAC among Moseten is currently underway. 
Only a minority of Tsimane and Moseten, mostly men, smoked regularly. The majority of people 
who did smoke only smoked a few cigarettes per month. We estimate that the average Tsimane 
‘smoker’ smoked < 0.3 pack years in their lifetime. Smoking is more common among Moseten: 
39% reported smoking regularly, and the average Moseten smoker smoked 2.6 pack years in their 
lifetime. 
Figure 1 Age-standardized 
atrial fibrillation prevalence 
ratios, with 95% CIs.  Ratios 
compare the observed 
prevalence in each population 
with the expected prevalence 
if that population had the 
average age-specific AF 
prevalences of a global GBD 
sample (2010 total prevalence 
of 1366/100,000), as reported 
by Chugh et al [12]. 
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AF PREVALENCE AND INCIDENCE
Tsimane
Only one of 1314 ECGs demonstrated AF (Table 2), yielding a crude prevalence rate of 0.076%, or < 
1 person per 1,000 (Table 3). There was one new AF case in 7395 risk years from 1059 adults with 
> 1 ECG. This represents a crude incidence rate of 0.14 per 1,000 risk years. 
Moseten
Only one of 534 ECGs demonstrated AF (Table 2), representing a crude prevalence of 0.187% 
(1.87 per 1,000). There were no new AF cases in 542 risk years from 311 adults with > 1 ECG 
(Table 3). Despite observing only one case of AF, we report three observations of premature atrial 
contractions, which are believed to play a critical role in AF pathogenesis in other populations [41, 
42]. No cases of atrial flutter were observed among either the Moseten or Tsimane.
Clinical Characteristics of All Three AF Cases
Case 1 (observed in Tsimane prevalence phase): The only person with AF on his first ECG was a 70-year-
old man in 2010. At last contact with the study in 2019, he was 79 years of age. Echocardiography 
demonstrated no valvular or structural heart disease and a normal ejection fraction. No other obvious 
AF risk factors were observed (BMI = 23 kg/m2, BP: 100/65 mmHg, total cholesterol = 137 mg/dL, LDL 
= 77 mg/dL, HbA1c = 5.6%). He has had five ECGs conducted by our project physicians from 2010 to 
2019, and AF was observed in all of them, consistent with permanent AF. 
Case 2 (observed in Tsimane incidence phase): The only adult who developed AF in the 
incidence phase was an 85-year-old woman whose first medical contact with our project was 
in 2010. She underwent a standard medical evaluation by a project physician, including an ECG 
and echocardiogram which demonstrated moderate aortic stenosis. She again received medical 
attention in August of 2016 for evaluation of an undiagnosed illness. Repeat echocardiography 
showed severe aortic stenosis and new AF based on the ECG. Three days later she went into 
pulseless electrical activity and died from end stage aortic stenosis; both prior ECGs showed normal 
sinus rhythm without left ventricular hypertrophy. Prior observations also showed no obvious AF 
risk factors (BMI = 20.1 kg/m2, BP: 100/60 mmHg, pulse: 68 bpm, total cholesterol = 94.9 mg/dL, 
LDL = 45.2 mg/dL). 
Case 3 (observed in Moseten prevalence phase): The only resident of a Moseten community with AF 
was a 72-year-old man. Though he resides in a Moseten village, he and his family migrated there from 
the Bolivian highlands and he is not of Moseten descent. AF was confirmed on two visits separated 
by two years (July 2016, July 2018), suggestive of long-standing persistent AF. Echocardiography 
demonstrated mild to moderate aortic stenosis in 2016. He was obese (BMI = 40.9 kg/m2, total body 
fat percentage = 38%), diabetic (fasting blood glucose = 241 mg/dL in 2016, and was 122 mg/dL in 
2018 after treatment), hypertensive (110/97 mmHg), had elevated resting heart rate (> 90 bpm on 
multiple occasions), but had low cholesterol (total cholesterol =132 mg/dL, LDL=70.4 mg/dL). 
Mortality Selection: One possibility for low AF prevalence and incidence is that the Tsimane or 
Moseten might experience a high AF case fatality rate given limited treatment options. However, 
our verbal autopsies revealed at most only two suspected cases where deaths could potentially 
be attributed to undiagnosed AF: an 88-year-old woman who died of a possible stroke, and a 
75-year-old man who died of an apparent myocardial infarction. Both of these individuals were in 
our ECG sample but had normal rhythm without conduction defects and no evidence of significant 
pathology prior to their death. It is therefore unlikely that mortality selection could account for the 
low AF prevalence and incidence rates we report here. 
TSIMANE AND MOSETEN AF IN COMPARATIVE PERSPECTIVE
In order to compare the Tsimane prevalence of AF to other populations, Figure 1 uses indirect 
standardization to compute age-standardized risk ratios of observed AF prevalence in diverse 
populations relative to the expected prevalence in those same populations if they had the average 
age-specific AF prevalences of a 2010 global reference sample from the Global Burden of Disease 
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study of AF [12]. The first cluster (in blue) represents four subsistence populations: the Tsimane, 
Moseten, and rural samples from Ghana and Tanzania [31, 32]. Prevalence rates across all four 
subsistence populations are exceedingly low, approximately 0.08–0.17 (1/12–1/6 as high as the 
global average), with overlapping confidence intervals. 
The second cluster represents aboriginal and native populations in the U.S., Canada and Australia, 
who no longer practice a subsistence-based lifestyle. While one Native American sample from the 
Strong Heart Study [33] shows a relatively low prevalence ratio, about 1/3 of the global reference, 
it is still 2–4 times higher than observed in subsistence populations. Two additional studies report 
higher AF prevalence among Native Americans. Ontario Métis natives show highly elevated 
prevalence (~50% higher) compared to non-native Canadians [35, 36, 43]. A larger sample of 
Native Americans from the Veteran’s Administration in 1999, though restricted to men, shows a 
much higher prevalence among Native Americans than what we report in Figure 1, similar to whites 
in that study [34]. More recent data show Native Americans of California to have higher incident AF 
than all other U.S. ethnic groups, attributed in part to excess chronic kidney disease and diabetes 
[44]. Australian Aborigines living in urban areas exhibit highly elevated AF prevalence, compared 
to the subsistence populations and global reference analyzed here, though this Aboriginal sample 
comes from urban hospital admissions over a 10-year period (and hence is not shown in Figure 1) 
[36]. In that study, Aborigines showed higher AF prevalence at younger ages (< 60 y) and lower AF 
prevalence at older ages (> 70 y) than non-indigenous Australians. 
As a regional comparison, we include tropical and Andean regions of Latin America. Both regions show 
rates 12–24% higher than the global reference. Western Europe and the GBD designation for ‘developing’ 
countries show similar AF prevalences as the global reference. North American AF prevalence is 43% 
higher, and the U.S. specifically is 58% higher, than the global reference. The Asia Pacific region shows 
the lowest AF prevalence for all post-industrialized countries, at 54% of the global reference.
DISCUSSION
AF is exceedingly rare among Tsimane and Moseten Amerindians of Bolivia: we found just one 
AF case in the prevalence phase of each population and one case in the incidence phase of the 
Tsimane. AF prevalence was therefore 8–18% that of Western Europe, and 5–11% that of the 
United States. It is also 15–31% that of Asia Pacific, which is the GBD world region with the lowest 
rates of AF [12]. The combined crude incidence rate of AF for Tsimane and Moseten is 0.13 per 
thousand risk years. 
Tsimane and Moseten exhibit minimal AF despite having several traditional risk factors, including 
elevated inflammatory biomarkers (e.g., CRP, IL-6, ESR [22]), and low HDL. The fact that AF is 
almost absent among Tsimane and Moseten suggests that the source of inflammation itself may 
play a role in AF etiology [17, 26]. In rural Bolivia, most inflammation comes from diverse infections 
(bacterial, parasitic, viral) that afflict individuals from a young age, while among many sedentary 
industrialized populations, the combination of obesity, cigarette smoking, air pollution, and 
other factors promotes chronic low-grade inflammation [45]. Given the heavy chronic infectious 
burden amongst the Tsimane and Moseten, and potential links between pathogen burden and the 
development of AF [46], one would expect to have found more cases of AF than observed. This 
interesting finding calls into question the particular inflammatory pathways that lead to AF. In 
industrialized populations, low HDL is also considered a moderate risk factor for AF [27]; this does 
not appear to be the case for Tsimane and Moseten, where over half of all individuals have low HDL 
but also low LDL and negligible AF risk.
AF has an exceptionally low prevalence in the four subsistence populations where it has been 
measured (Figure 1) [31, 32]. While many traditional AF risk factors were low in these populations, the 
two African populations showed higher levels of hypertension, suggesting that hypertension alone 
is insufficient to increase AF risk. Despite being the most common medical condition associated 
with AF worldwide [6], hypertension likely must interact with other cardiovascular disease risk 
factors like dyslipidemia, diabetes, and sedentary lifestyle to increase AF susceptibility. Low AF risk 
among the two African populations, and in sub-Saharan African countries more generally, are also 
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noteworthy given high reported stroke incidences in the region [47]. AF patients in sub-Saharan 
Africa also tend to be younger than in other world regions, and experience high case fatality and 
rheumatic valvular heart disease [48]. AF incidence is expected to increase substantially in sub-
Saharan Africa over the next few decades [12, 48], highlighting the need for more research on 
AF etiology in the region. The Tsimane and Moseten also exhibit greater systemic inflammation 
and lower HDL than other subsistence populations, but this does not appear to lead to greater AF 
prevalence. These observations in subsistence populations suggest that multiple risk factors in 
concert may be necessary to increase AF risk. 
Despite the fact that Moseten lead a more modernized lifestyle than Tsimane, they do not 
manifest significantly higher AF prevalence or incidence. As most lifestyle differences among 
Moseten have occurred in the past three decades, it is possible that older Moseten have largely 
had similar cumulative exposures as age-matched Tsimane. Our results therefore suggest that 
lifecourse, or perhaps particularly early life, exposures warrant consideration beyond biomarkers 
assessed in later adulthood. An expectation is that differences in AF incidence, and presumably 
CVD, diabetes, and related comorbidities, will increasingly manifest in younger adults over time. 
LIMITATIONS
In order to reduce measurement bias when assessing AF prevalence, we took steps to make sure 
that people who were not sampled (n = 68 individuals, 4.6% of the study population) were not 
missed due to illness or other comorbidities that could be associated with AF. However, people 
not sampled were likely among the healthiest, either traveling to other villages or locations during 
team visits, or too busy working that they declined medical attention (very few individuals, Figure 
S1, S2). 
While mortality selection might explain why indigenous Australians have higher AF prevalence 
than non-indigenous Australians only before age 60 years [36], it does not explain the low levels 
of AF risk we report among Tsimane and Moseten. Consistent with what we report for verbal 
autopsies, an earlier study examining retrospective causes of death among Tsimane similarly 
reported minimal evidence of strokes or infarcts [49]. A study of stroke incidence among another 
Bolivian Amazonian population (Chiquitano) also reported very low incidence (174/100,000) over 
a one-year period [50].
Another potential weakness is that we only performed resting 12-lead ECGs, which sample 10 
seconds at a time. With our methodology, it would be difficult to detect cases of intermittent 
or paroxysmal AF. It has been proposed that paroxysmal AF may be more common in some 
ethnicities than the persistent AF usually reported for Caucasians, especially among ethnicities 
with higher stroke risk [51]. Thus, it is possible that we and others using similar methods may be 
underestimating AF. Indeed, the use of higher-sensitivity detection methods has been shown to 
reduce ethnic differences in AF prevalence [52]. Nevertheless, the comparative data from other 
population-level studies relied on similar ECG methodology, and so our results are comparable to 
most studies reported in Figure 1. 
Lastly, we acknowledge that ~140 genetic loci affecting AF have been identified to date among 
participants mostly of European descent [53]. Genetic risk prediction of AF is still in its infancy, 
and the relevance of these loci and ancestry-specific rare variants in contributing to the low 
AF prevalence among Tsimane, Moseten, and other subsistence populations remains to be 
determined. 
CONCLUSION
Our findings of exceptionally low AF prevalence and incidence among rural Bolivian horticulturalists 
suggest that a subsistence lifestyle with high rates of physical activity and a diet relatively 
low in processed carbohydrates and harmful fats can be heart-healthy despite high levels of 
inflammation and low HDLs. Some lifestyle alterations associated with incipient modernization 
may be insufficient to increase AF risk, as suggested here by similar AF prevalences among 
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Tsimane and Moseten. AF prevalence is higher among indigenous populations that are no longer 
living a traditional subsistence lifestyle, suggesting that combined changes in physical activity, 
diet, and other risk factors associated with marginalization, discrimination, and lifestyle disruption 
can increase vulnerability to AF, especially when coupled with low access to quality healthcare. 
Rather than being viewed as an inevitable feature of cardiovascular aging, it appears that AF is 
better viewed as a modifiable lifestyle disease with ample scope for prevention. 
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ADDITIONAL FILES
The additional files for this article can be found as follows:
•	 Supplementary Figure S1: STROBE Diagram for Tsimane subject recruitment. N = 1871 
refers to all Tsimane who were at least age 40 years from 2005–2019, considering that the 
THLHP medical team sampled adults age 40+ throughout the entire study period (i.e. not 
only at baseline). N = 1314 adults had at least one ECG. 557 adults were not sampled, either 
because ECGs were not measured on all medical rounds (most common, largely due to 
damaged equipment, lack of electricity, and in some cases lack of time), or because adults 
were either not present in the village during visits when ECGs assessed (common reason), 
or were present in the community but did not show up for their clinical visit (less common). 
255 adults were lost to follow-up, due either to not being in the village during follow-up 
visits (most common), being present but not showing up for their clinical visit (less common), 
or being seen by project physicians but refusing an ECG (rare). DOI: https://doi.org/10.5334/
aogh.3252.s1
•	 Supplementary Figure S2: STROBE Diagram for Moseten subject recruitment. The prevalence 
phase is based on one medical round in 2015–2016; incidence phase is based on a follow-
up visit in 2017–2018. Of the 561 eligible Moseten aged 40+ years, 20 were either not 
present in the community during THLHP visits (most common), or were present but did not 
visit our mobile clinic (less common). Loss to follow-up during the second visit was due to 
not revisiting all of the same villages seen during the prevalence phase, and slightly poorer 
attendance at our clinic. DOI: https://doi.org/10.5334/aogh.3252.s2
•	 Supplementary Table S1: Potential sample bias in prevalence and incidence phases. 
Biomarker comparisons between those who received or did not receive an ECG during the 
prevalence phase, and those who did or did not receive a follow-up ECG in the incident 
phase. Mean values are compared using student t-tests. Blue color indicates lower AF risk 
among unsampled adults, whereas red color indicates higher AF risk. In the prevalence 
phase, unsampled Tsimane and Moseten are similar or show lower AF risk than those 
sampled with an ECG. In the incidence phase, Tsimane from the prevalence phase who were 
lost to follow-up ECG showed only slightly higher AF risk than those sampled (2.1 years older, 
2.6 mg/dL lower HDL, 1.8 mmHg higher systolic blood pressure, 6.5 mm/hr higher ESR), 
though also show lower AF risk for LDL (14 mg/dL lower) and total cholesterol (13.3 mg/dL 
lower). Among Moseten, those lost to follow-up showed only slightly higher BMI (0.9 kg/m2 
higher). DOI: https://doi.org/10.5334/aogh.3252.s3
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